APA (7th ed.) Citation

Caraballo Galva, L. D., Jiang, X., Hussein, M. S., Zhang, H., Mao, R., Brody, P., . . . He, Y. (2022). Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology (Baltimore, Md.), 76(2), 330-344. https://doi.org/10.1002/hep.32279

Chicago Style (17th ed.) Citation

Caraballo Galva, Leidy D., et al. "Novel Low‐avidity Glypican‐3 Specific CARTs Resist Exhaustion and Mediate Durable Antitumor Effects Against HCC." Hepatology (Baltimore, Md.) 76, no. 2 (2022): 330-344. https://doi.org/10.1002/hep.32279.

MLA (9th ed.) Citation

Caraballo Galva, Leidy D., et al. "Novel Low‐avidity Glypican‐3 Specific CARTs Resist Exhaustion and Mediate Durable Antitumor Effects Against HCC." Hepatology (Baltimore, Md.), vol. 76, no. 2, 2022, pp. 330-344, https://doi.org/10.1002/hep.32279.